Literature DB >> 11321238

Characterization of the impaired antipneumococcal polysacharide antibody production in immunosuppressed pediatric patients following cardiac transplantation.

A R Gennery1, A J Cant, C I Baldwin, J E Calvert.   

Abstract

We previously have demonstrated impaired pneumococcal polysaccharide IgG antibody responses in children immunosuppressed following cardiac transplantation in early childhood. We have further characterized the antibody defect. To further investigate the production of antibody, antipneumococcal polysaccharide (PPS) specific IgM, IgG, IgG subclasses, and IgA were measured in postvaccination sera by enzyme-linked immunosorbent assay. Two groups were studied: posttransplant children who made pneumococcal antibody in vivo following natural exposure or PPS immunization (R) and those with an impaired response (NR). There was no difference in IgM or IgA levels between R and NR. IgG and IgG2 levels were higher in R than NR (P = 0.002), even after adsorption of nonspecific common cell wall antigen antibody. Differences in anti-pneumococcal antibody levels suggest that immunoglobulin isotype switching from IgM to IgG and particularly IgG2 is impaired in patients immunosuppressed at a young age. These findings confirm data regarding the effect of immunosuppressive agents derived from animal models in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11321238     DOI: 10.1023/a:1006793032290

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  26 in total

1.  Drug-induced immunological tolerance.

Authors:  R SCHWARTZ; W DAMESHEK
Journal:  Nature       Date:  1959-06-13       Impact factor: 49.962

2.  Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?

Authors:  D M Musher; D A Watson; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

3.  Antibody responses to pneumococcal capsular polysaccharide: what is being measured?

Authors:  D Goldblatt; L P Jadresic; R J Levinsky; M W Turner
Journal:  Immunodeficiency       Date:  1993

4.  Antibody deficiency with normal immunoglobulins.

Authors:  C Rothbach; J Nagel; B Rabin; P Fireman
Journal:  J Pediatr       Date:  1979-02       Impact factor: 4.406

5.  Effects of cyclosporin A on the immune system of the mouse. I. Evidence for a direct selective effect of cyclosporin A on B cells responding to anti-immunoglobulin antibodies.

Authors:  D W Dongworth; G G Klaus
Journal:  Eur J Immunol       Date:  1982-12       Impact factor: 5.532

6.  The acquisition of anti-pneumococcal capsular polysaccharide Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK.

Authors:  M Hazlewood; R Nusrat; D S Kumararatne; M Goodall; C Raykundalia; D G Wang; H J Joyce; A Milford-Ward; M Forte; A Pahor
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

7.  Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.

Authors:  H Peltola; H Käyhty; A Sivonen; H Mäkelä
Journal:  Pediatrics       Date:  1977-11       Impact factor: 7.124

8.  Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency.

Authors:  D T Umetsu; D M Ambrosino; I Quinti; G R Siber; R S Geha
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

9.  Predictors of infection in chronic lymphocytic leukaemia (CLL).

Authors:  H Griffiths; J Lea; C Bunch; M Lee; H Chapel
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

10.  EFFECT OF 6-MERCAPTOPURINE (6-MP) ON DIFFERENT CLASSES OF ANTIBODY.

Authors:  Y BOREL; M FAUCONNET; P A MIESCHER
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.